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Letter to the Editor
One advantage yet to focus on in scientific literature 
is the beneficial use of virtual autopsy (virtopsy) for 
investigating minimal tumor burden. Our hypothesis 
is that virtopsy assists in the understanding of therapy 
resistance of cancer patients or cause of death in patients 
with minimal tumor burden.1 The well-established 
textbook scenario describes a patient dying from 
cancer by the tumor mass compressing surrounding 
tissue (e.g. brain tumors), or destroying surrounding 
tissue resulting in organ failure (e.g. multi-metastatic 
diseases), or destroying blood vessels causing lethal 
bleeding.
Furthermore, patients may die from tumor-induced 
cachexia, which is a consequence of the tumor’s 
interference with the body’s energy homeostasis. 
However there are some instances when it is difficult 
to explain a tumor-related death, particularly when a 
patient dies of head or neck cancer. For example, when 
major tumor mass is not detectable, there are no signs 
of cachexia, or evidence of an immediate consequence 
of chemotherapy or radiotherapy. When patients might 
die exhibiting a small metastasis in the lung or a small 
local tumor, it is concluded that they died of the cancer 
because there is no other apparent cause of death 
(e.g. cardiac disease). This is concluded despite none 
of the classical cancer-related causes of death being 
established. In view of this therefore is an unexplained 
mechanism of how a tumor can kill a patient.
The majority of current cancer therapies are 
aimed at killing tumor cells. This is done either 
direct ly (by chemical  agents or radiat ion),  or 
indirectly (by depriving the tumor from nutrients, 
or activating and redirecting the immune response 
against the cancer). This variety of therapeutic 
approaches is reflected in modern therapies such as 
PDL-1 blockers, VEGF-inhibitors, tumor-vaccines or 
Proteasome-inhibitors. However the observation that 
a fair number of patients with minimal detectable 
tumor mass die of cancer, given that treatment 
options described were considered, highlights gaps in 
knowledge that require filling as well as development 
of new potential therapeutic approaches.
As a first step we propose epidemiological studies 
be undertaken - these are required in order to obtain 
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quantifiable data on how many and which type of 
cancer patients die of cancer with minimal tumor 
mass. As autopsies are rarely performed on patients 
whose cancer has been well-characterized during 
the course of the disease, systematic data on this 
poorly-characterized cause of cancer-related death 
do not exist. Furthermore, the assessment of total 
tumor mass in the body is difficult in disseminated 
diseases by traditional autopsy. In cases where 
minimal tumor burden has caused patients to die, 
we need to gain more knowledge (evidence-based 
practice). It is the combination of autopsy, pathology 
and virtopsy that truly defines or examines the entire 
body. When dealing with a localized disease, traditional 
autopsy is appropriate in order to cut out, weigh and 
measure parts that are affected. This however, cannot 
be performed when dealing with a disseminated 
disease with many small lesions in various organ 
systems. Virtopsy can be a very effective intervention 
to quantify tumor mass. Imaging would provide very 
important baseline data to compare different patients’ 
tumor mass and to exclude other non-cancer-related 
causes of death.1 Machine learning methods will also 
be of great assistance too, particularly for potential 
in-silico modelling.2,3 This would save time and effort; 
enabling what is not currently feasible in a wet-lab. 
Moreover, the principles of machine learning image 
analysis would enhance virtopsy.1
The enormous practical success of Machine 
Learning and Artificial Intelligence (AI) has led to 
more evidence-based decision-making in the medical 
domain.4 A very recent example with deep learning 
models demonstrated impressive results:5 the authors 
utilized a GoogleNet Inception v3 CNN architecture for 
the classification of skin lesions, using only pixels and 
disease labels as inputs. They pre-trained their network 
with 1.28 million images (1,000 object categories), 
and trained it on 129,450 clinical images, consisting 
of 2,032 different diseases. The performance was 
tested against 21 board-certified dermatologists on 
biopsy-proven clinical images with two critical binary 
classification use cases: keratinocyte carcinomas 
versus benign seborrheic keratoses; and malignant 
melanomas versus benign nevi.
The results demonstrated that such deep learning 
models can achieve a performance even beyond human 
experts. However, besides being resource-intensive 
and data-hungry, black-box machine learning and 
AI approaches have one enormous disadvantage in the 
medical domain – they are lacking transparency. Even if 
we understand the mathematical theory of machine 
learning model it is complicated, yet impossible to 
get insight into the internal working of such a model. 
This leads to a major question – can we trust such results?
Consequently, there is growing demand in 
interactive machine learning advances,6 which are not 
only well performing, but transparent, interpretable 
and trustworthy and include a human-in-the-loop.7 
For the medical domain it is necessary to re-enact 
the machine decision-making process, to reproduce 
and to comprehend the learning and knowledge 
extraction process.8 For medical decision support it 
is of ultimate importance to understand the causality 
of learned representations.9,10 If human intelligence 
will be complemented by machine learning and at 
least in some cases even take precedence, humans 
must be able to understand and principally be able to 
interactively influence the machine decision process. 
This needs to make sense in order to close the gap 
between human thinking and machine “thinking”.11
Increasing legal and privacy characteristics are a 
massive motivation for this practice. The new European 
General Data Protection Regulation (GDPR and 
ISO/IEC 27001) entering into force on May, 25, 2018, 
will make black-box approaches difficult to use in any 
business, because they recognize that they are not 
able to explain why a decision has been made; this will 
make glass-box approaches essential12 and stimulate 
international research in interactive machine learning 
with the goal of making decisions interpretable, 
comprehensible and reproducible. In our example, this 
is not only useful for machine learning research, and 
for clinical decision making, but at the same time a big 
asset for the training of medical students.
We therefore call for a collaborative effort to 
generate quantifiable data on tumor burden of patients 
who died of cancer without evidence of classical 
causes of cancer-related deaths. These data could 
lay the foundation for discovering novel mechanisms 
of how a cancer may interfere with body function. 
There is increasing evidence from metabolomic 
studies that tumors may markedly interfere with 
metabolism as demonstrated by certain metabolic 
signatures that correlate with disease prognosis.13 
Interestingly this interference was not related to signs 
of cachexia, and therefore is most likely different to 
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presently-described mechanisms of cancer-induced 
cachexia.14 A broadening of the scientific basis on the 
relevance of metabolic interference of cancer could 
widen the field of cancer therapies, which target the 
cancer interference with the patient’s metabolism.15
In summary, this article presents and supports an 
add-on example of how virtopsy can propel medicine 
into the future, its impact, implications and application 
in investigating minimal tumor burden and therapy 
resistance by cancer patients. Great advances will 
be made by taking advantage of current progress in 
Machine Learning and Artificial Intelligence, however 
new approaches are needed that make use of a 
human-in-the-loop and above all in making transparent 
why and how a decision has been made.
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